Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II/III studies
Stephen R. Marder, W. Wolfgang Fleischhacker, Willie Earley, et al.
European Neuropsychopharmacology (2018) Vol. 29, Iss. 1, pp. 127-136
Open Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology
Stephen Kaar, Sridhar Natesan, Robert A. McCutcheon, et al.
Neuropharmacology (2019) Vol. 172, pp. 107704-107704
Closed Access | Times Cited: 283
Maintenance treatment with antipsychotic drugs for schizophrenia
Anna Ceraso, Jingxia Lin, Johannes Schneider‐Thoma, et al.
Cochrane library (2020) Vol. 2020, Iss. 8
Open Access | Times Cited: 132
Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety
I. Laszlovszky, Ágota Barabássy, György Németh
Advances in Therapy (2021) Vol. 38, Iss. 7, pp. 3652-3673
Open Access | Times Cited: 59
The efficacy of cariprazine on cognition: a post hoc analysis from phase II/III clinical trials in bipolar mania, bipolar depression, and schizophrenia
Roger S. McIntyre, David G. Daniel, Eduard Vieta, et al.
CNS Spectrums (2022) Vol. 28, Iss. 3, pp. 319-330
Open Access | Times Cited: 44
Adjunctive Cariprazine for the Treatment of Patients With Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study
Gary S. Sachs, Paul Yeung, Ludmyla Rekeda, et al.
American Journal of Psychiatry (2023) Vol. 180, Iss. 3, pp. 241-251
Closed Access | Times Cited: 31
Towards Enhancing Drug Development Methodology to Treat Cognitive Impairment Associated With Schizophrenia and Other Neuropsychiatric Conditions: Insights From 2 Decades of Clinical Trials
W. P. Horan, Amir H Kalali, Stephen K. Brannan, et al.
Schizophrenia Bulletin (2025)
Open Access | Times Cited: 1
Dopamine D3 receptor: A neglected participant in Parkinson Disease pathogenesis and treatment?
Pengfei Yang, Joel S. Perlmutter, Tammie L.S. Benzinger, et al.
Ageing Research Reviews (2019) Vol. 57, pp. 100994-100994
Open Access | Times Cited: 73
Developments in Biological Mechanisms and Treatments for Negative Symptoms and Cognitive Dysfunction of Schizophrenia
Qiongqiong Wu, Xiaoyi Wang, Ying Wang, et al.
Neuroscience Bulletin (2021) Vol. 37, Iss. 11, pp. 1609-1624
Open Access | Times Cited: 41
New Antipsychotic Medications in the Last Decade
Mehak Pahwa, Ahmad Sleem, Omar H. Elsayed, et al.
Current Psychiatry Reports (2021) Vol. 23, Iss. 12
Closed Access | Times Cited: 35
The real-world impact of cariprazine on short- and long-term disability outcomes among commercially insured patients in the United States
Prakash S. Masand, Mousam Parikh, Jamie T. Ta, et al.
Journal of Medical Economics (2025), pp. 1-29
Open Access
Healthcare resource utilization and costs of using Cariprazine as the first versus subsequent adjunctive therapy for major depressive disorder
Prakash S. Masand, Anita H. Clayton, Mousam Parikh, et al.
Journal of Medical Economics (2025) Vol. 28, Iss. 1, pp. 235-244
Open Access
Frequency, correlates and outcomes of Benzodiazepine use during Cariprazine treatment: A pooled post-hoc analysis from four 6-week, placebo-controlled trials in patients with an acute exacerbation of schizophrenia
Christoph U. Correll, Réka Csehi, K. Acsai, et al.
European Neuropsychopharmacology (2025) Vol. 94, pp. 76-83
Closed Access
Improving Mood and Cognitive Symptoms in Huntington's Disease With Cariprazine Treatment
Mária Judit Molnár, Viktor Molnár, Mariann Fedor, et al.
Frontiers in Psychiatry (2022) Vol. 12
Open Access | Times Cited: 17
Current perspectives in treating negative symptoms of schizophrenia: A narrative review (Review)
Octavia Căpățînă, I. Micluția, Mihaela Fadgyas Stănculete
Experimental and Therapeutic Medicine (2021) Vol. 21, Iss. 3
Open Access | Times Cited: 22
The More, the Merrier…? Antipsychotic Polypharmacy Treatment Strategies in Schizophrenia From a Pharmacology Perspective
Stephan Hjorth
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 18
Dosing Cariprazine Within and Beyond Clinical Trials: Recommendations for the Treatment of Schizophrenia
Elmārs Rancāns, Z.B. Dombi, Ágota Barabássy
Frontiers in Psychiatry (2022) Vol. 12
Open Access | Times Cited: 13
Adjunctive cariprazine as a novel effective strategy for treating major depressive disorder: A systematic review and meta-analysis
Minjia Xie, Youjia Qiu, Menghan Wang, et al.
Journal of Psychiatric Research (2024) Vol. 172, pp. 71-80
Closed Access | Times Cited: 2
GABAergic and inflammatory changes in the frontal cortex following neonatal PCP plus isolation rearing, as a dual-hit neurodevelopmental model for schizophrenia
Jennifer Cale, Ethan J. Chauhan, Joshua J. Cleaver, et al.
Molecular Neurobiology (2024) Vol. 61, Iss. 9, pp. 6968-6983
Open Access | Times Cited: 2
Case Report: Cariprazine in a Patient With Schizophrenia, Substance Abuse, and Cognitive Dysfunction
José Rodriguez Cruz, Johan Sahlsten Schölin, Stephan Hjorth
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 16
Widespread Changes in Positive Allosteric Modulation of the Muscarinic M1 Receptor in Some Participants With Schizophrenia
Shaun Hopper, Geoffrey Pavey, Andrea Gogos, et al.
The International Journal of Neuropsychopharmacology (2019) Vol. 22, Iss. 10, pp. 640-650
Open Access | Times Cited: 19
Remission of Persistent Negative Symptoms and Psychosocial Consequences by Combined Clozapine and Cariprazine Treatment in a Patient With Long-Standing Treatment-Resistant Schizoaffective Disorder
Mats Bogren, Monica Soltesz, Stephan Hjorth
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 10
Real-Life Clinical Experience With Cariprazine: A Systematic Review of Case Studies
Réka Csehi, Z.B. Dombi, B. Sebe, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 9
The improvement of motor symptoms in Huntington’s disease during cariprazine treatment
Réka Csehi, Viktor Molnár, Mariann Fedor, et al.
Orphanet Journal of Rare Diseases (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 4
Treatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine
Borjanka Batinić, Ivan Ristić, Milica Žugić, et al.
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 10
Case Report: Functional and Symptomatic Improvement With Cariprazine in Various Psychiatric Patients: A Case Series
Tommaso Vannucchi, Costanza Taddeucci, L. Tatini
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top